PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)
Blocking the PI3K growth pathway alongside hormone therapy works only when the tumour carries a mutation in that pathway, and works best early.
SOLAR-1 (alpelisib), CAPItello-291 (capivasertib), and INAVO120 (inavolisib with palbociclib and fulvestrant; OS HR 0.67) all show benefit restricted to, or largest in, PIK3CA/AKT1/PTEN-altered tumours. Toxicity (hyperglycaemia, rash, diarrhoea) differs by agent and shapes choice.
Pages like this
not linked directly; found by shared links- TrialCAPItello-291
Shares Fulvestrant, Capivasertib, AKT, PIK3CA / PI3K-alpha.
- TrialSOLAR-1
Shares Alpelisib, Fulvestrant, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares Inavolisib, Fulvestrant, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- PersonRamon E. Parsons
Shares AKT, PIK3CA / PI3K-alpha, PI3K / AKT / mTOR, HR-positive / HER2-negative breast cancer.
- TrialCAPItello-281
Shares Capivasertib, AKT, PI3K / AKT / mTOR.
- ProductGedatolisib
Shares AKT, PIK3CA / PI3K-alpha, PI3K / AKT / mTOR, HR-positive / HER2-negative breast cancer.
- PersonFabrice André
Shares Alpelisib, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
- TermHyperglycaemia (PI3K/AKT inhibitor class effect)
Shares Alpelisib, Capivasertib.